Introduction
Multiple myeloma (MM) is a plasma cell neoplasm characterized by the accumulation of malignant plasma cells primarily in the bone marrow (BM). A majority of patients with MM develop osteolytic bone disease characterized by bone pain, pathologic fractures, and hypercalcemia, due to the disruption of the coupling of osteoclastic bone resorption and osteoblastic bone formation 1 . An increase in [ ] bone turnover rate was reported to precede progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to overt 
Osteoclasts
Osteoclasts were generated as previously described 9 . In brief, peripheral blood mononuclear cells were obtained from 7 patients with 
In vitro cell migration assay
For Transwell migration assay, 24-well plates with transwell inserts (6.5 mm diameter, 5 m pore size; Costar Corning Elscolab) and μ RPMI 1640 medium (Life Technologies) supplemented with 0.5 BSA (Sigma-Aldrich) were used. The inserts were coated with 100 l % μ human fibronectin solution (Invitrogen) at a concentration of 10 g/ml in distilled water and incubated for 1h at 37 C and 5 CO2. The μ°% solution was removed and the inserts were dried for 2 hrs at 37 C. The lower transwell chamber containing osteoclasts was filled with 600 °l of MEM-10 FCS. 10 MMC were added to the upper chamber. Cells were then allowed to migrate for 90 min at 37 C in a humid Growth assay for myeloma cells 3 16 HMCLs were IL-6-and serum-starved for 2 hours and cultured for 4 days in 96-well flat-bottom microtiter plates in serum-free culture medium without cytokine (control), with rIL-6 (2 ng/mL) or with graded CCL2, CCL7, CCL8, CCL13, or CCL23 concentrations. The growth of myeloma cells was evaluated by quantifying intracellular ATP with a Cell Titer Glo Luminescent Assay (Promega, Madison, WI) with a Centro LB 960 luminometer (Berthold Technologies, Bad Wildbad, Germany).
Elisa
The concentrations of BAFF, APRIL, IL-10, IL-6, and IGF-1 were assayed with ELISAs purchased from Bender MedSystems 
Preparation of complementary RNA (cRNA) and microarray hybridization
RNA extraction was performed using the RNeasy kit (QIAGEN, Hilden, Germany), the SV-total RNA extraction kit (Promega, Mannheim, Germany) and Trizol (Invitrogen, Karlsruhe, Germany). Labeled cRNA was generated using the small sample labeling protocol vII (Affymetrix, Santa Clara, CA), and hybridized to U133 2.0 plus arrays according to the manufacturer s instructions.
'
Fluorescence intensities were quantified and analyzed using the GECOS software (Affymetrix).
All microarray data presented in this paper have been deposited in the ArrayExpress public database, under accession numbers E-MEXP-2360 for BMPC 23 and E-TABM-937 for B cells, PPC, MMC and environment population samples.
[ ]
Real-time RT-PCR
Total RNA was converted to cDNA using the Superscript II reverse transcriptase (Invitrogen, Cergy Pontoise, France). The assays-on-demand primers and probes and the Man Universal Master Mix were used according to the manufacturer s instructions Taq ' (Applied Biosystems, Courtaboeuf, France). The measurement of gene expression was performed using the ABI Prism 7000 Sequence Detection System and analyzed using the ABI PRISM 7000 SDS Software. For each set of primers, serial dilutions of a standard cDNA were amplified to create a standard curve, and values of unknown samples were estimated relative to this standard curve in order to assess the PCR efficiency. Ct values were obtained for GAPDH and the respective genes of interest during log phase of the cycle. Gene of interest levels were normalized to GAPDH for each sample ( Ct Ct gene of interest Ct GAPDH) and compared with the values 
Statistical analysis
Gene expression data were normalized with the MAS5 algorithm and analyzed with our bioinformatics platform -RAGE 4 16 To identify osteoclast-associated factors that could promote MMC survival, we investigated genes overexpressed in osteoclasts compared to either BM CD14 monocytes, BM CD15 polymorphonuclear cells, BM CD34 cells, BM stromal cells, or BM B cells using supervised SAM analysis (ratio 2, FDR 1 , 1000 permutations). Genes overexpressed in osteoclasts compared to normal BM plasma ≥ ≤ % cells or primary MMC were also determined. Crossing these gene lists yielded 552 genes/expressed sequence tags (ESTs) significantly overexpressed in osteoclasts compared to the 7 BM cell populations (Supplemental Table S1 ). These genes were significantly ( < .05) P enriched in genes encoding for 2 major pathways -cellular function and maintenance and cell-to cell signaling and interaction as well
Results

Identification of cell communication signals involved in MMC/osteoclast interactions
as 10 other pathways (supplementary Figure S1 ).
Osteoclasts express genes coding for CCR2-chemokines specifically and high gene expression in myeloma cells is associated CCR2 with increased bone lesions Seven of the 552 osteoclast genes encoded for chemokines ( Figure 1A and Table S2 ). Four of these chemokines (CCL2, CCL7, CCL8 and CCL13) target the CCR2 receptor expressed by myeloma cells 25 
CCR2
MM could be linked with increased bone lesions. The gene expression on normal and malignant plasma cells is depicted in Figure  CCR2 1B. The reliability of the Affymetrix probe set (206978_at) to assay for gene expression was validated characterizing protein CCR2 expression by flow cytometry in HMCLs. A strong correlation between CCR2 gene and protein expression was found (r .90, P < .001, Table 1 ). This signal cutoff is 2.7 fold the median value of signal in normal plasma cells. Of note, since osteoclasts CCR2 CCR2
specifically express the gene coding for CCL23 that activates CCR1 weakly, we also studied whether expression in MMC could be CCR1 linked with bone lesion extent. Contrarily to CCR2, no cutoff of gene expression in MMC could identify a group of CCR1 newly-diagnosed patients with increased bone lesions. An explanation is that various cells in the bone marrow environment could produce other CCR1-targeting chemokines. This is the case for MIP1-/CCL3 whose gene is expressed by osteoclasts but also by monocytes, α stromal cells, and MMC as mentioned above. This data suggests these chemokines could be important to recruit MMC to the bone marrow but not specifically close to osteoclasts.
Role of CCR2-chemokines in the osteoclast chemoattractant activity for myeloma cells
The chemoattractant activity of osteoclasts for MMC was evaluated using the XG-6, XG-19, and LP1 HMCLs. XG-19 and XG-6 myeloma cells express CCR2 gene and protein, unlike LP1 myeloma cells (Figure 2 ). Osteoclasts could efficiently attract XG-19 and XG-6 cells, unlike LP1 cells in a transwell assay. This chemoattractant activity was inhibited by a neutralizing MoAb to CCR2 by 95% and 81 for the XG-19 and XG-6 cells respectively ( .05, Figure 2B ). As osteoclasts express chemokine gene together Figure 2B ). Addition of both anti-CCR1 and anti-CCR2 P ≤ MoAbs further inhibited the osteoclast-mediated migration of myeloma cells ( Figure 2B ). Similar data were obtained with primary myeloma cells of 5 patients ( Figure 2C&D ). Primary myeloma cells variably expressed CCR2 or CCR1 assayed by flow cytometry depending on patients sample. Osteoclasts could attract more than 4 primary myeloma cells for 3 out of the 5 patients, the highest ' % chemoattraction being observed with primary myeloma cells with the highest CCR2 and CCR1 expression ( Figure 2C&D ). The osteoclast chemotactic activity was inhibited by a neutralizing anti-CCR2 MoAb ( < .05, Figure 2D ). It was also inhibited by a neutralizing P anti-CCR1 MoAb ( < .05, Figure 2D ) P
CCR2-chemokines activate MAP kinase pathway in myeloma cells and promote myeloma cell growth and a MAP kinase inhibitor abrogates the chemoattractant activity of osteoclasts to myeloma cells
The recombinant CCL7, CCL8, and CCL13 CCR2-chemokines significantly increased the growth of CCR2 XG-19 cells and only + CCL8 that of XG-6 cells ( .05, Figure 3A ). These chemokines did not stimulate the growth of CCR2 LP1 cells ( Figure 3A ). CCL7 and P ≤ [ ] in CCR1 CCR2 LP1 cells ( Figure 3B ). As the osteoclast chemoattractant activity for MMC was inhibited by anti-CCR2 MoAbs and as − − CCR2-chemokines activated MAPK pathway in MMC, we looked for the effect of a MAP kinase inhibitor on osteoclast chemoattractant activity for MMC. The PD98059 MAP kinase inhibitor dramatically inhibited the migration of myeloma cells towards osteoclasts ( Figure   3C ).
Growth factors produced by osteoclasts
Osteoclasts overexpress genes encoding for previously reported MGFs, including IGF-1 33 , IL-10 34 and APRIL 32 ( Figures 4A) .
and genes are also highly expressed by osteoclasts but were not picked in the osteoclast gene list because they are also highly IL-6 BAFF expressed by BM stromal cells ( ), monocytes, or polymorphonuclear cells ( )( Figure 4A ). Osteoclasts produced IGF-1 or APRIL IL-6 BAFF proteins. 418 16 pg/ml of IGF-1 and 5 0.3 ng/ml of APRIL were detected in 3-day culture supernatants of osteoclasts ( Figure 4B ),
concentrations that are active on myeloma cells 32,33 . Osteoclasts also produced IL-6 (141 13 pg/mL) and BAFF (1.6 0.5 ng/mL) and Figure S4) , whereas it blocked efficiently their chemoattractant activity ( Figure 2B ).
Osteoclasts promote the survival of primary MMC
Purified primary MMC rapidly apoptosed within 2 days 36 and adding recombinant IL-6 did not prevent apoptosis. A in vitro [ ] coculture with osteoclasts completely prevented primary MMC from apoptosis on day 2 and this protective effect lasted until day 6 ( Figure   5 B) . Given the rarity of primary MMC, it was not possible to add the inhibitors to the various growth factors produced by osteoclasts to identify those that are critical.
Discussion
The aim of this study was to identify some major cell communication signals involved in recruitment of MMC close to osteoclasts and subsequent support of MMC survival 4,37 .
We first identified 552 genes that are significantly overexpressed in osteoclasts compared to various cell components of the BM microenvironment and to MMC. Comparing our results with previous gene array analyses of osteoclasts, 22 common genes coding for secreted or extracellular matrix proteins were identified in Pederson s study 38 and in our current study, in particular , and
CCL7, CCL8
chemokine genes and and genes (Table S2 ). This stringent method was initially chosen to limit the size of the CXCL5 RANK, IGF-1 IL-10 osteoclast gene list, being aware that some genes that are highly expressed both in osteoclasts and in another cell population could be eliminated. Our data show this method is of interest to find the signals that may attract MMC specifically to osteoclasts and promote MMC survival.
There are about 50 chemokines 39 , some of them being already found to be produced in the bone marrow milieu of patients with MM: show that the expression of CCR2-chemokines is very specific to osteoclasts, whereas it was previously shown that various cells including
Blood . Author manuscript Page / 6 16 osteoclasts produce the MIP-1 /CCL3 CCR1-chemokine 13,14 . This suggests that a myeloma cell that expresses CCR1 could be recruited The current data suggest that osteoclasts can directly recruit MMC by producing CCR2-chemokines, promote MMC survival, growth and drug resistance by producing various growth factors. Vice versa, MMC will further promote osteoclast progenitor recruitment and differentiation producing MIP1-/CCL3, MIP-1 , and CXCL12 chemokines, IGF-1, and increasing RANKL production by stromal cells [ ]
In conclusion, we have identified an additional mechanism involved in the interaction of osteoclasts and MMC. Osteoclasts are the main cells in the bone marrow environment that produce various CCR2-chemokines enabling malignant plasma cells attraction.
Osteoclasts also produce the major growth factors for MMC IGF-1, IL-6, APRIL. Targeting the osteoclast/MMC interaction through -CCR2 and/or IGF-1 appears to be a promising therapeutic approach in myeloma.
Acknowledgements: 7 16 This work was supported by grants from the Ligue Nationale Contre le Cancer ( quipe labellis e CCL7, CCL8 and CCL13 support the growth of CCR2 HMCLs + A. XG-19, LP1 and XG-6 were IL-6 starved for 3 hours and cultured either with no cytokine, or in the presence of IL-6 (3 ng/mL) or in the presence of increasing concentrations of CCL2, CCL7, CCL8 or CCL13. 
Figure 5
Osteoclasts promote the survival of cytokine-dependent myeloma cell lines A. XG-19 and XG-20 myeloma cells were cultured at 10 cells/ml without cytokine, or with IL-6 (2 ng/ml), or with 10 osteoclasts with or 5 4 without anti-IL-6 (BE8) MoAb (10 g/ml), TACI-Fc (20 g/ml), anti-IGF-1R MoAb (4 g/ml), anti-IL-10 MoAb (10 g/ml) or anti-CCR2 Table 2 XG-19 and XG-20 HMCLs were cultured at 10 cells/ml without cytokine or with IL-6 (2 ng/ml), or with 10 osteoclasts with or without anti-IL-6 (B 5 4 anti-IGF-1R MoAb (4 mg/ml), anti-IL-10 MoAb (10 mg/ml) or anti-CCR2 MoAb (10 mg/ml). Cells were recovered after 3 days of culture and apopto 
